Gaucher disease (GD) is a rare inborn error of metabolism, classified as a lipid storage disorders. This disease is caused by a deficiency in glucocerebrosidase enzyme. It has been classified according to the presence or absence of neurological symptoms into the following types: type 1 non-neuropathic, type 2 acute infantile neuropathic and type 3 or chronic neuropathic. We evaluated neurological symptoms in patients with GD1 and GD3 and compared both of these groups.
Introduction
Gaucher disease (GD) is the most common disease of inborn error of metabolism. It is an autosomal recessive lipid storage disorder, caused by a defect in the gene that encodes β-glucocerebrosidase (GBA gene). months of age and patients usually die before 2 yr of age not discussed in our study (9) .
In GD3, the most common symptoms are skeletal abnormalities, eye movement disorders, respiratory problems, blood disorders and brain involvement.
The brain abnormalities manifest gradually, as seizures, cognitive deficits, and poor coordination.
Eye movement abnormalities, such as horizontal saccadic eye movements, have also been reported in type 3 (10) .
In this study, we evaluated neurological symptoms in the patients with GD1 and GD3 and compared both of these groups.
Materials & Methods
Patients with symptoms suggestive of Gaucher disease were screened, selected and followed The data were analyzed by descriptive methods and no statistical testing was applied as observational study.
Results
Eleven patients with the diagnosis of GD1 (8 patients) and GD3 (3 patients) were included.
The enzymatic study showed decreased β-Glucocerebrosidase activity and diagnosis was further confirmed by genetic testing (Table 1) . Chief complaints expressed by GD1 patients at the time of presentation consisted as follows:
Abdominal distention and discomfort due to hepatosplenomegaly were seen in 75% of patients, epistaxis due to thrombocytopenia in 25% of patients, anorexia and weight loss in 25%, also, limb pain with difficulty walking in one patient.
Chief complaints in primary presentation of patients with GD3 were similar to patients with GD1, with hepatosplenomegaly in all of GD3 patients, epistaxis in one patient, and anorexia and weight loss in two patients. Additionally, there was delay in teeth growth in all of them.
Neurological problems were detected in all of eight patients with GD1 and included: cognitive impairment in one patient (13%), developmental delay and microcephaly in four patients (50%), behavioral disorder, mild spasticity and increased
DTR in three patients (in 37%).
On the other hand, neurological findings in three patients with GD3 were developmental delay in all of them as well as cerebellar dysfunction, and Most of previous studies have been done in adult patients, so they often noticed early dementia and Parkinsonism in neurological presentation of their GD1 patients, but we studied on children and mean age of our patients at the bingeing of assessment was 4.36 yr, so our patients presented with different pattern with spasticity, developmental delay, microcephaly, and so on.
Another study reported neurologic complications in patients with GD1 secondary to systemic features of the illness, such as CNS bleeding due to coagulopathy, or abnormal gait induced by skeletal disease (8) . However, our patients had spasticity, increased DTR, microcephaly and other signs that
were not justified by primary problems such as coagulopathy, or skeletal disease.
Another study reported neurological manifestations of GD1 and according to recent information deducted that may discuss Gaucher's classification and the existence of a continuum between neuropathic and non-neuropathic forms of the GD disease (7).
Thus, according to our assessment, patients with GD1 have variety of neurological problems such as developmental delay, microcephaly, behavioral disorders, spasticity, and so on, although some kinds of neurological involvements such as myoclonic seizure, supranuclear gaze palsy, cerebellar sign, and ataxia, are more typically seen in GD3 patients.
However, unlike previous studies that mentioned GD type 3 and type 1 differentiated by existence of neurological involvements in type 3, we found that type 1 could also be presented with some neurological deficits. Therefore, the neurological symptoms are not the important criteria for differentiation between different types of more gauche disease, and genetic testing is required for confirmation of diagnosis and determining a treatment plan. 
